PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Войти

Зарегистрироваться
Забыли пароль?

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20170730 184021
20170730 175154
20170731 015714
DJI 0039
20180130 171733
20180202 160137
  • Human medicines European public assessment report (EPAR): Adrovance, alendronic acid,colecalciferol, Osteoporosis, Postmenopausal, Date of authorisation: 04/01/2007, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Trixeo Aerosphere, formoterol,glycopyrronium bromide,budesonide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 09/12/2020, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Ovitrelle, choriogonadotropin alfa, Anovulation;Reproductive Techniques, Assisted;Infertility, Female, Date of authorisation: 02/02/2001, Revision: 22, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Neutropenia;Hematopoietic Stem Cell Transplantation;Cancer, Date of authorisation: 06/02/2009, Revision: 23, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Graft Rejection, Date of authorisation: 14/02/1996, Revision: 38, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Lixiana, edoxaban, Stroke;Venous Thromboembolism, Date of authorisation: 19/06/2015, Revision: 18, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Riltrava Aerosphere, formoterol fumarate dihydrate,glycopyrronium,budesonide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 06/01/2022, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Human medicines European public assessment report (EPAR): Roteas, edoxaban, Stroke;Venous Thromboembolism, Date of authorisation: 19/04/2017, Revision: 11, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
  • Biological Products - Specific Labeling Resources
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
  • GDUFA Type II API DMF Payment Receipts Report
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
  • GDUFA Paid Facilities List
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
  • PDUFA and BsUFA Quarterly Hiring Updates
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
  • Coronavirus (COVID-19) | CBER-Regulated Biologics
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-10-03 By FDA
  • FDA Roundup: October 3, 2023
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
  • FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-10-03 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.